Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management

References

• Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. EBioMedicine. 2022;76:103820. doi: 10.1016/j.ebiom.2022.103820
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) world impact survey (iWish): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188–98. doi: 10.1002/ajh.26045
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Cetin K, Mægbæk ML, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174(4):639–42. doi: 10.1111/bjh.13787
   PubMed Web of Science ®Google Scholar
• Doobaree IU, Nandigam R, Bennett D, et al. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016;97(4):321–30. doi: 10.1111/ejh.12777
   PubMed Web of Science ®Google Scholar
• Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database. Haematologica. 2010;95(7):1167–1175. doi: 10.3324/haematol.2009.018390
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. Is ITP a thrombophilic disorder? Am J Hematol. 2016;91(1):39–45. doi: 10.1002/ajh.24234
   PubMed Web of Science ®Google Scholar
• van Dijk WEM, Brandwijk ON, Heitink-Polle KMJ, et al. Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients. Blood Rev. 2021;47:100774. doi: 10.1016/j.blre.2020.100774
   PubMed Web of Science ®Google Scholar
• Cooper N, Altomare I, Thomas MR, et al. Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib. Ther Adv Hematol. 2021;12:1–12. doi: 10.1177/20406207211010875
   Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–23. doi: 10.3324/haematol.2018.212845
   PubMed Web of Science ®Google Scholar
• Han X, Li C, Zhang S, et al. Why thromboembolism occurs in some patients with thrombocytopenia and treatment strategies. Thromb Res. 2020;196:500–9. doi: 10.1016/j.thromres.2020.10.005
   PubMed Web of Science ®Google Scholar
• Abou-Ismail MY, Kapoor S, Citla Sridhar D, et al. Thrombotic microangiopathies: an illustrated review. Res Pract Thromb Haemost. 2022;6(3):e12708. doi: 10.1002/rth2.12708
   PubMed Web of Science ®Google Scholar
• Saxon BR, Blanchette VS, Butchart S, et al. Reticulated platelet counts in the diagnosis of acute immune thrombocytopenic purpura. J Pediatr Hematol Oncol. 1998;20(1):44–8. doi: 10.1097/00043426-199801000-00007
   PubMed Web of Science ®Google Scholar
• Kaito K, Otsubo H, Usui N, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol. 2005;128(5):698–702. doi: 10.1111/j.1365-2141.2004.05357.x
   PubMed Web of Science ®Google Scholar
• Frojmovic M, Wong T. Dynamic measurements of the platelet membrane glycoprotein IIb-IIIa receptor for fibrinogen by flow cytometry. II. Platelet size-dependent subpopulations. Biophys J. 1991;59(4):828–837. doi: 10.1016/s0006-3495(91)82295-0
   PubMed Web of Science ®Google Scholar
• Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest. 1969;48(6):1083–7. doi: 10.1172/jci106064
   PubMed Web of Science ®Google Scholar
• Thompson CB, Jakubowski JA, Quinn PG, et al. Platelet size as a determinant of platelet function. J Lab Clin Med. 1983;101(2):205–213.
   PubMed Web of Science ®Google Scholar
• Handtke S, Thiele T. Large and small platelets-(when) do they differ? J Thromb Haemost. 2020;18(6):1256–1267. doi: 10.1111/jth.14788
   PubMed Web of Science ®Google Scholar
• Alvarez-Roman MT, Fernandez-Bello I, Jimenez-Yuste V, et al. Procoagulant profile in patients with immune thrombocytopenia. Br J Haematol. 2016;175(5):925–34. doi: 10.1111/bjh.14412
   PubMed Web of Science ®Google Scholar
• Jy W, Johansen ME, Bidot C Jr., et al. Red cell-derived microparticles (RMP) as haemostatic agent. Thromb Haemost. 2013;110(4):751–760. doi:10.1160/TH12-12-0941
   PubMed Web of Science ®Google Scholar
• Zucker-Franklin D, Karpatkin S. Red-cell and platelet fragmentation in idiopathic autoimmune thrombocytopenic purpura. N Engl J Med. 1977;297(10):517–23. doi: 10.1056/nejm197709082971001
   PubMed Web of Science ®Google Scholar
• Greene LA, Chen S, Seery C, et al. Beyond the platelet count: immature platelet fraction and thromboelastometry correlate with bleeding in patients with immune thrombocytopenia. Br J Haematol. 2014;166(4):592–600. doi: 10.1111/bjh.12929
   PubMed Web of Science ®Google Scholar
• Lukasik ZM, Makowski M, Makowska JS. From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders. Rheumatol Int. 2018;38(6):959–74. doi: 10.1007/s00296-018-4001-9
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–509. doi: 10.1016/S0140-6736(10)60709-X
   PubMed Web of Science ®Google Scholar
• Enger C, Bennett D, Forssen U, et al. Comorbidities in patients with persistent or chronic immune thrombocytopenia. Int J Hematol. 2010;92(2):289–95. doi: 10.1007/s12185-010-0636-3
   PubMed Web of Science ®Google Scholar
• Severinsen MT, Engebjerg MC, Farkas DK, et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2011;152(3):360–2. doi: 10.1111/j.1365-2141.2010.08418.x
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Severinsen MT, Lund Maegbaek M, et al. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012;159(1):109–11. doi: 10.1111/j.1365-2141.2012.09231.x
   PubMed Web of Science ®Google Scholar
• Uthman I, Godeau B, Taher A, et al. The hematologic manifestations of the antiphospholipid syndrome. Blood Rev. 2008;22(4):187–194. doi:10.1016/j.blre.2008.03.005
   PubMed Web of Science ®Google Scholar
• Arfors L, Winiarski J, Lefvert AK. Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Eur J Haematol. 1996;56(4):230–4. doi: 10.1111/j.1600-0609.1996.tb01934.x
   PubMed Web of Science ®Google Scholar
• Lipp E, von Felten A, Sax H, et al. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol. 1998;60(5):283–8. doi:10.1111/j.1600-0609.1998.tb01041.x
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84(12):4203–8. doi: 10.1182/blood.V84.12.4203.bloodjournal84124203
   PubMed Web of Science ®Google Scholar
• Diz-Küçükkaya R, Hacihanefioğlu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98(6):1760–1764. doi: 10.1182/blood.v98.6.1760
   PubMed Web of Science ®Google Scholar
• Pierrot-Deseilligny C, Khellaf M, Gouault M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in adults with immune Thrombocytopenic Purpura. Blood. 2006;108(11):1083. doi: 10.1182/blood.V108.11.1083.1083
   Web of Science ®Google Scholar
• Bidot CJ, Jy W, Horstman LL, et al. Antiphospholipid antibodies in immune thrombocytopenic purpura tend to emerge in exacerbation and decline in remission. Br J Haematol. 2005;128(3):366–72. doi: 10.1111/j.1365-2141.2004.05314.x
   PubMed Web of Science ®Google Scholar
• Bidot CJ, Jy W, Horstman LL, et al. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol. 2006;81(6):391–6. doi:10.1002/ajh.20571
   PubMed Web of Science ®Google Scholar
• Moulis G, Audemard-Verger A, Arnaud L, et al. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis. Autoimmun Rev. 2016;15(3):203–9. doi: 10.1016/j.autrev.2015.11.001
   PubMed Web of Science ®Google Scholar
• Sun S, Urbanus RT, Ten Cate H, et al. Platelet activation mechanisms and consequences of immune thrombocytopenia. Cells. 2021;10(12):3386. doi: 10.3390/cells10123386
   PubMed Web of Science ®Google Scholar
• Machin N, Ragni MV, Comer DM, et al. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: an NIS study. Thromb Res. 2018;172:80–5. doi:10.1016/j.thromres.2018.10.017
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Gridley G, Hoover RN, et al. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014;99(2):392–8. doi: 10.3324/haematol.2013.092460
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi: 10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–30. doi: 10.1002/ajh.25125
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–8. doi: 10.1016/s0140-6736(09)60402-5
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402. doi: 10.1016/s0140-6736(10)60959-2
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–36. doi: 10.1182/blood-2017-04-748707
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–94. doi: 10.1182/blood-2013-07-514398
   PubMed Web of Science ®Google Scholar
• Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–90. doi: 10.1111/bjh.15573
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. doi: 10.1016/s0140-6736(08)60203-2
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–71. doi: 10.1182/blood-2008-04-150078
   PubMed Web of Science ®Google Scholar
• Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8(6):1372–82. doi: 10.1111/j.1538-7836.2010.03830.x
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–23. doi: 10.1111/bjh.12260
   PubMed Web of Science ®Google Scholar
• Janssens A, Rodeghiero F, Anderson D, et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016;95(7):1077–87. doi: 10.1007/s00277-016-2682-2
   PubMed Web of Science ®Google Scholar
• Guitton Z, Terriou L, Lega J-C, et al. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology. 2018;57(8):1432–8. doi: 10.1093/rheumatology/key119
   PubMed Web of Science ®Google Scholar
• Girolami A, de Marinis GB, Bonamigo E, et al. Arterial and venous thromboses in patients with idiopathic (immunological) thrombocytopenia: a possible contributing role of cortisone-induced hypercoagulable state. Clin Appl Thromb Hemost. 2013;19(6):613–618. doi: 10.1177/1076029612452114
   PubMed Web of Science ®Google Scholar
• Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology. 2015;2015(1):237–42. doi: 10.1182/asheducation-2015.1.237
   PubMedGoogle Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi: 10.1182/bloodadvances.2019000812
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630–8. doi: 10.1001/archinte.160.11.1630
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, et al. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315. doi:10.1182/blood-2014-05-578336
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909–13. doi:10.1182/blood.V94.3.909.415k02_909_913
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145(2):235–44. doi: 10.1111/j.1365-2141.2009.07615.x
   PubMed Web of Science ®Google Scholar
• Swan D, Newland A, Rodeghiero F, et al. Thrombosis in immune thrombocytopenia - current status and future perspectives. Br J Haematol. 2021;194(5):822–834. doi: 10.1111/bjh.17390
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. ITP and thrombosis: an intriguing association. Blood Adv. 2017;1(24):2280. Epub 20171114. doi: 10.1182/bloodadvances.2017007989
   PubMed Web of Science ®Google Scholar
• Justo Sanz R, Monzon Manzano E, Fernandez Bello I, et al. Platelet apoptosis and PAI-1 are involved in the pro-coagulant state of immune thrombocytopaenia patients treated with thrombopoietin receptor agonists. Thromb Haemost. 2019;119(4):645–59. doi: 10.1055/s-0039-1678706
   PubMed Web of Science ®Google Scholar
• Alvarez Roman MT, Fernandez Bello I, Arias-Salgado EG, et al. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thromb Haemost. 2014;112(1):65–72. doi: 10.1160/TH13-10-0873
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. FDA approves fostamatinib tablets for ITP. [ Updated 2018 Apr 18; cited 2023 Dec 20] Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fostamatinib-tablets-itp
   Google Scholar
• European Medicines Agency. Tavlesse. fostamatinib. [ Updated 2022 Sep 12; cited 2023 Dec 20]. Availablefrom: https://www.ema.europa.eu/en/medicines/human/EPAR/tavlesse
   Google Scholar
• Newland A, Lee EJ, McDonald V, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25. doi: 10.2217/imt-2017-0097
   PubMed Web of Science ®Google Scholar
• Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94(5):546–53. doi: 10.1002/ajh.25444
   PubMed Web of Science ®Google Scholar
• Boccia R, Cooper N, Ghanima W, et al. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol. 2020;190(6):933–8. doi: 10.1111/bjh.16959
   PubMed Web of Science ®Google Scholar
• Kuwana M, Ito T, Kowata S, et al. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study. Br J Haematol. 2023;200(6):802–11. doi: 10.1111/bjh.18582
   PubMed Web of Science ®Google Scholar
• Lhermusier T, van Rottem J, Garcia C, et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost. 2011;9(10):2067–76. doi: 10.1111/j.1538-7836.2011.04470.x
   PubMed Web of Science ®Google Scholar
• Spalton JC, Mori J, Pollitt AY, et al. The novel syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost. 2009;7(7):1192–9. doi:10.1111/j.1538-7836.2009.03451.x
   PubMed Web of Science ®Google Scholar
• Strich JR, Ramos-Benitez MJ, Randazzo D, et al. Fostamatinib inhibits neutrophils extracellular traps induced by COVID-19 patient plasma: a potential therapeutic. J Infect Dis. 2021;223(6):981–4. doi: 10.1093/infdis/jiaa789
   PubMed Web of Science ®Google Scholar
• Strich JR, Tian X, Samour M, et al. Fostamatinib for the treatment of hospitalized adults with COVD-19 a randomized trial. Clin Infect Dis. 2022;75(1):e491–8. doi: 10.1093/cid/ciab732
   PubMed Web of Science ®Google Scholar
• Wigerblad G, Warner SA, Ramos-Benitez MJ, et al. Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. Sci Adv. 2023;9(1):eade8272. doi: 10.1126/sciadv.ade8272
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Double-blind, randomized, placebo-controlled, multi-center phase 3 study to evaluate the efficacy and safety of fostamatinib in COVID-19 subjects. [ Updated 2023 Aug 18; cited 2023 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04629703?term=fostamatinib&cond=COVID-19&draw=2&rank=2
   Google Scholar
• Clinicaltrials.gov. Inflammatory signal inhbitors for COVID-19 (MATIS). [ Updated Jul 2022; cited 20 Dec 2023]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04581954
   Google Scholar
• Clinicaltrials.gov. Novel experimental COVID-19 therapies affecting host response (NECTAR). [ Updated 2023 Dec 5; cited 2023 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04924660?term=fostamatinib&cond=COVID-19&draw=2&rank=4
   Google Scholar
• Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014;12(8):1266–73. doi: 10.1111/jth.12636
   PubMed Web of Science ®Google Scholar